4. JUSTIFICATIVA
6.10. ANÁLISE ESTATÍSTICA
Todos os ensaios propostos foram validados por testes estatísticos adequados a cada modalidade (os dados foram submetidos a teste de distribuição normal). Os resultados foram expressos em média ±SEM. Comparações foram realizadas usando análise de variância (ANOVA) seguida por fator de correção Newman-Keuls para comparações múltiplas. Teste T foi utilizado para comparação de dois grupos. Diferenças entre as médias foram consideradas significantes quando os valores de p foram menores que 0,05. Todos os dados estão expressos em média ± s.e.m.
53 7. REFERÊNCIAS
Abu-Soud, H. M., Hazen, S. L., 2000. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem. 275, 5425-30.
Albini, A., et al., 2005. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 65, 10637-41.
Aldaba-Muruato, L. R., et al., 2013. Allopurinol reverses liver damage induced by chronic carbon tetrachloride treatment by decreasing oxidative stress, TGF-beta production and NF-kappaB nuclear translocation. Pharmacology. 92, 138-49.
Alimonda, A. L., et al., 2009. Hyperuricemia in acute heart failure. More than a simple spectator? Eur J Intern Med. 20, 74-9.
Almeida, S. A., et al., 2014. Natriuretic peptide clearance receptor ligand (C- ANP4-23 ) attenuates angiogenesis in a murine sponge implant model. Clin Exp Pharmacol Physiol. 41, 691-7.
Andrade, S. P., et al., 1987. Quantitative in-vivo studies on angiogenesis in a rat sponge model. Br J Exp Pathol. 68, 755-66.
Andrade, S. P., Ferreira, M. A., 2009. The sponge implant model of angiogenesis. Methods Mol Biol. 467, 295-304.
Andrade, S. P., et al., 1997. Sponge-induced angiogenesis in mice and the pharmacological reactivity of the neovasculature quantitated by a fluorimetric method. Microvasc Res. 54, 253-61.
Araujo, F. A., et al., 2011. Implant-induced intraperitoneal inflammatory angiogenesis is attenuated by fluvastatin. Clin Exp Pharmacol Physiol. 38, 262-8.
54 Araujo, F. A., et al., 2010. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed Pharmacother. 64, 29-34.
Arenberg, D. A., et al., 1997a. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol. 62, 554-62. Arenberg, D. A., et al., 1997b. In vitro and in vivo systems to assess role of C-X-
C chemokines in regulation of angiogenesis. Methods Enzymol. 288, 190- 220.
Aronson, J. K., 2007. Old drugs--new uses. Br J Clin Pharmacol. 64, 563-5. Ashburn, T. T., Thor, K. B., 2004. Drug repositioning: identifying and developing
new uses for existing drugs. Nat Rev Drug Discov. 3, 673-83.
Aslan, M., et al., 2001. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 98, 15215-20.
Bailey, P. J., 1988. Sponge implants as models. Methods Enzymol. 162, 327-34. Baldwin, W., et al., 2011. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 60, 1258-69.
Barcelos, L. S., et al., 2005. Impaired inflammatory angiogenesis, but not leukocyte influx, in mice lacking TNFR1. J Leukoc Biol. 78, 352-8.
Belo, A. V., et al., 2004. Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice. Life Sci. 74, 2827-37.
Belo, A. V., et al., 2001. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation. 25, 91-6.
55 Benelli, R., et al., 2006. Cytokines and chemokines as regulators of angiogenesis
in health and disease. Curr Pharm Des. 12, 3101-15.
Bernardini, G., et al., 2003. Analysis of the role of chemokines in angiogenesis. J Immunol Methods. 273, 83-101.
Berry, C. E., Hare, J. M., 2004. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 555, 589-606.
Bieber, J. D., Terkeltaub, R. A., 2004. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 50, 2400-14.
Borish, L. C., Steinke, J. W., 2003. 2. Cytokines and chemokines. J Allergy Clin Immunol. 111, S460-75.
Bradshaw, A. D., et al., 2001. Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Repair Regen. 9, 522-30.
Brandes, R. P., Kreuzer, J., 2005. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 65, 16-27.
Broeders, M. A., et al., 1998. Endogenous nitric oxide protects against thromboembolism in venules but not in arterioles. Arterioscler Thromb Vasc Biol. 18, 139-45.
Burton, L. K., et al., 1995. Xanthine oxidase contributes to lung leak in rats subjected to skin burn. Inflammation. 19, 31-8.
Butcher, E. C., 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 67, 1033-6.
56 Campos, P. P., et al., 2006. Cellular proliferation, differentiation and apoptosis in polyether-polyurethane sponge implant model in mice. Histol Histopathol. 21, 1263-70.
Campos, P. P., et al., 2008. Mechanisms of wound healing responses in lupus- prone New Zealand White mouse strain. Wound Repair Regen. 16, 416- 24.
Chang, C., Werb, Z., 2001. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 11, S37-43. Charo, I. F., Ransohoff, R. M., 2006. The many roles of chemokines and
chemokine receptors in inflammation. N Engl J Med. 354, 610-21.
Charo, I. F., Taubman, M. B., 2004. Chemokines in the pathogenesis of vascular disease. Circ Res. 95, 858-66.
Chidlow, J. H., Jr., et al., 2010. VEGF(1)(6)(4) differentially regulates neutrophil and T cell adhesion through ItgaL- and ItgaM-dependent mechanisms. Am J Physiol Gastrointest Liver Physiol. 299, G1361-7.
Coussens, L. M., Werb, Z., 2002. Inflammation and cancer. Nature. 420, 860-7. D'Amore, P. A., Thompson, R. W., 1987. Mechanisms of angiogenesis. Annu Rev
Physiol. 49, 453-64.
de Oliveira, T. B., et al., 2007. Oxidative stress in chronic cardiopathy associated with Chagas disease. Int J Cardiol. 116, 357-63.
de Souza, C. M., et al., 2014. Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model. Biomed Pharmacother. 68, 51-7.
Doehner, W., et al., 2002. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients
57 with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 105, 2619-24.
Dvorak, H. F., 2005. Angiogenesis: update 2005. J Thromb Haemost. 3, 1835- 42.
Fernandez, M. L., et al., 2012. Elevated uric acid correlates with wound severity. Int Wound J. 9, 139-49.
Fernandez, M. L., et al., 2014. Uric acid and xanthine oxidoreductase in wound healing. Curr Rheumatol Rep. 16, 396.
Ferreira, M. A., et al., 2004. Sponge-induced angiogenesis and inflammation in PAF receptor-deficient mice (PAFR-KO). Br J Pharmacol. 141, 1185-92. Folkman, J., Greenspan, H. P., 1975. Influence of geometry on control of cell
growth. Biochim Biophys Acta. 417, 211-36.
Folkman, J., Klagsbrun, M., 1987. Vascular physiology. A family of angiogenic peptides. Nature. 329, 671-2.
Ford, C. W., et al., 1989. Establishment of an experimental model of a Staphylococcus aureus abscess in mice by use of dextran and gelatin microcarriers. J Med Microbiol. 28, 259-66.
Freedman, J. E., 2008. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol. 28, s11-6.
George, J., Struthers, A. D., 2009. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vascular health and risk management. 5, 265-72.
Giler, S., et al., 1977. Elevation of serum xanthine oxidase activity following halothane anesthesia in man. Experientia. 33, 1356-8.
58 Giler, S., et al., 1976. Elevated serum xanthine oxidase activity following biliary
tract and gastric surgery. Int Surg. 61, 153-5.
Glantzounis, G. K., et al., 2005. Uric acid and oxidative stress. Curr Pharm Des. 11, 4145-51.
Godber, B. L., et al., 2000. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem. 275, 7757-63.
Gormus, Z. I., et al., 2013. Does preoperative administration of allopurinol protect the lungs from ischemia-reperfusion injury occuring during cardiopulmonary bypass? Bratisl Lek Listy. 114, 561-5.
Granger, D. N., Senchenkova, E., 2010.
Greenhalgh, D. G., 1996. The role of growth factors in wound healing. J Trauma. 41, 159-67.
Grell, M., et al., 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83, 793-802.
Griendling, K. K., 2004. Novel NAD(P)H oxidases in the cardiovascular system. Heart. 90, 491-3.
Grisham, M. B., et al., 1986. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol. 251, G567-74.
Gupta, S., 2002. A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol. 22, 185-94.
Gupta, S. C., et al., 2013. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 34, 508-17.
Guthikonda, S., et al., 2003. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 107, 416-21.
59 Harrison, R., 2002. Structure and function of xanthine oxidoreductase: where are
we now? Free Radic Biol Med. 33, 774-97.
Harrison, R., 2004. Physiological roles of xanthine oxidoreductase. Drug Metab Rev. 36, 363-75.
Hestin, D., Johns, E. J., 1999. The influence of allopurinol on kidney haemodynamic and excretory responses to renal ischaemia in anaesthetized rats. Br J Pharmacol. 128, 255-61.
Hicklin, D. J., Ellis, L. M., 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23, 1011-27. Houston, M., et al., 1999. Binding of xanthine oxidase to vascular endothelium.
Kinetic characterization and oxidative impairment of nitric oxide- dependent signaling. J Biol Chem. 274, 4985-94.
Kayyali, R., et al., 1998. Comparative radical scavenging ability of bidentate iron (III) chelators. Biochem Pharmacol. 55, 1327-32.
Kelley, E. E., et al., 2010. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free radical biology & medicine. 48, 493-8.
Kida, M., Lenz, W., 1968. [Thalidomide embryopathy in Japan]. Arch Kinderheilkd. 177, 244-59.
Kou, B., et al., 2008. Xanthine oxidase interaction with vascular endothelial growth factor in human endothelial cell angiogenesis. Microcirculation. 15, 251-67.
Koutroubakis, I. E., et al., 2006. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis. 12, 515-23.
60 Kuebler, W. M., et al., 1996. Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. Int J Microcirc Clin Exp. 16, 89-97.
Kumar, V., et al., 2008. Effect of clarithromycin on lung inflammation and alveolar macrophage function in Klebsiella penumoniae B5055-induced acute lung infection in BALB/c mice. J Chemother. 20, 609-14.
Kuppahally, S., et al., 2006. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 6, 986-92.
Lenz, W., 1966. Malformations caused by drugs in pregnancy. Am J Dis Child. 112, 99-106.
Liekens, S., et al., 2001. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 61, 253-70.
Linas, S. L., et al., 1990. Role of xanthine oxidase in ischemia/reperfusion injury. Am J Physiol. 258, F711-6.
Maeshima, Y., et al., 2000. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 275, 23745-50.
Malik, U. Z., et al., 2011. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free radical biology & medicine. 51, 179-84.
Manning, A. S., et al., 1984. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res. 55, 545-8.
61 Mantovani, A., et al., 1997. Endothelial activation by cytokines. Ann N Y Acad
Sci. 832, 93-116.
Margaritis, E. V., et al., 2011. Effects of oral administration of (L)-arginine, (L)- NAME and allopurinol on intestinal ischemia/reperfusion injury in rats. Life Sci. 88, 1070-6.
Marques, S. M., et al., 2011. Genetic background determines mouse strain differences in inflammatory angiogenesis. Microvasc Res. 82, 246-52. Matthews, S. J., McCoy, C., 2003. Thalidomide: a review of approved and
investigational uses. Clin Ther. 25, 342-95.
McManaman, J. L., et al., 1999. Mouse mammary gland xanthine oxidoreductase: purification, characterization, and regulation. Arch Biochem Biophys. 371, 308-16.
Mendes, J. B., et al., 2009. Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. Microvasc Res. 78, 265-71.
Mignatti, P., Rifkin, D. B., 1996. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 49, 117-37.
Millar, T. M., et al., 2002. Xanthine oxidase is a peroxynitrite synthase: newly identified roles for a very old enzyme. Redox Rep. 7, 65-70.
Moses, M. A., 1997. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 15, 180-9.
Moura, S. A., et al., 2011. Local drug delivery system: inhibition of inflammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants. J Pharm Sci. 100, 2886-95.
62 Mrowietz, U., Boehncke, W. H., 2006. Leukocyte adhesion: a suitable target for
anti-inflammatory drugs. Curr Pharm Des. 12, 2825-31.
Murphy, G., et al., 1999. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci. 878, 25-39.
Murphy, K. E., et al., 2011. A two-compartment mechanochemical model of the roles of transforming growth factor beta and tissue tension in dermal wound healing. J Theor Biol. 272, 145-59.
Nagy, V., et al., 2008. Thrombophilic screening in retinal artery occlusion patients. Clin Ophthalmol. 2, 557-61.
Nathan, C., 2002. Points of control in inflammation. Nature. 420, 846-52.
Nielsen, V. G., et al., 1994. Xanthine oxidoreductase release after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg. 107, 1222-7.
Nunes, P. S., et al., 2011. Collagen-based films containing liposome-loaded usnic acid as dressing for dermal burn healing. J Biomed Biotechnol. 2011, 761593.
O'Reilly, M. S., et al., 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88, 277-85.
Otrock, Z. K., et al., 2007. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis. 39, 212- 20.
Oviedo-Socarras, T., et al., 2014. Diabetes alters inflammation, angiogenesis, and fibrogenesis in intraperitoneal implants in rats. Microvasc Res. 93, 23- 9.
63 Pacher, P., et al., 2006. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 58, 87-114.
Pea, F., 2005. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 147, 35-46.
Pereira, F. O., et al., 2006. Evaluation of tumour necrosis factor alpha, interleukin- 2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm. 2006, 39062. Pesonen, E. J., et al., 1998. Circulating xanthine oxidase and neutrophil activation
during human liver transplantation. Gastroenterology. 114, 1009-15. Peto, K., et al., 2005. [Determination of urinary NAG to detect renal ischemia-
reperfusion injury and the protective effect of Allopurinol]. Magy Seb. 58, 134-7.
Peuckmann, V., et al., 2003. [Novel potential uses of thalidomide in the management of pain? A review of the literature]. Schmerz. 17, 204-10. Phillips, R. J., et al., 2004. Circulating fibrocytes traffic to the lungs in response
to CXCL12 and mediate fibrosis. J Clin Invest. 114, 438-46.
Poggetti, R. S., et al., 1992. Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J Trauma. 32, 723-7; discussion 727-8.
Polytarchou, C., Papadimitriou, E., 2004. Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. Free Radic Res. 38, 501-8.
Prakash, S., Robbins, P. W., 2001. Fibrosin: a novel lymphokine in wound healing. Exp Mol Pathol. 71, 247-55.
64 Puig, J. G., Martinez, M. A., 2008. Hyperuricemia, gout and the metabolic
syndrome. Curr Opin Rheumatol. 20, 187-91.
Rhoden, E., et al., 2000. The effects of allopurinol in hepatic ischemia and reperfusion: experimental study in rats. Eur Surg Res. 32, 215-22.
Rollins, B. J., 1997. Chemokines. Blood. 90, 909-28.
Rott, K. T., Agudelo, C. A., 2003. Gout. JAMA. 289, 2857-60.
Saban-Ruiz, J., et al., 2013. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm Antiallergy Agents Med Chem. 12, 94-9.
Sampaio, F. P., et al., 2012. Genetic background determines inflammatory angiogenesis response to dipyridamole in mice. Exp Biol Med (Maywood). 237, 1084-92.
Savvatis, K., et al., 2010. Kinins in cardiac inflammation and regeneration: insights from ischemic and diabetic cardiomyopathy. Neuropeptides. 44, 119-25.
Schlesinger, N., 2004. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 64, 2399-416.
Sedgwick, J. B., et al., 2002. Effects of inflammatory cytokines on the permeability of human lung microvascular endothelial cell monolayers and differential eosinophil transmigration. J Allergy Clin Immunol. 110, 752-6.
Sherry, B., Cerami, A., 1988. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol. 107, 1269-77.
65 Slevin, M., et al., 2009. Controlling the angiogenic switch in developing atherosclerotic plaques: possible targets for therapeutic intervention. J Angiogenes Res. 1, 4.
Tan, C. M., et al., 1995. Oxidant stress enhances adenylyl cyclase activation. Circ Res. 77, 710-7.
Tan, S., et al., 1998. Endothelial injury from a circulating mediator following rat liver ischemia. Free Radic Biol Med. 24, 427-34.
Tan, S., et al., 1993. Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic Biol Med. 15, 407-14.
Tartaglia, L. A., Goeddel, D. V., 1992. Two TNF receptors. Immunol Today. 13, 151-3.
Terada, L. S., et al., 1992. Circulating xanthine oxidase mediates lung neutrophil sequestration after intestinal ischemia-reperfusion. Am J Physiol. 263, L394-401.
Terkeltaub, R. A., 2003. Clinical practice. Gout. N Engl J Med. 349, 1647-55. Thuraisingam, T., et al., 2010. MAPKAPK-2 signaling is critical for cutaneous
wound healing. J Invest Dermatol. 130, 278-86.
Tracey, K. J., 2002. The inflammatory reflex. Nature. 420, 853-9.
Ushio-Fukai, M., Urao, N., 2009. Novel role of NADPH oxidase in angiogenesis and stem/progenitor cell function. Antioxid Redox Signal. 11, 2517-33. Vianna, F. S., et al., 2013. Polymorphisms in the endothelial nitric oxide synthase
gene in thalidomide embryopathy. Nitric Oxide. 35, 89-92.
Visser, L., et al., 2006. Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am J Pathol. 169, 1671-85.
66 White, C. R., et al., 1996. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A. 93, 8745-9.
Wortmann, R. L., 2005. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol. 17, 319-24.
Wright, H. L., et al., 2010. Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford). 49, 1618-31.
Xavier, D. O., et al., 2010. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother. 64, 220-5.
Yokoyama, Y., et al., 1990. Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Physiol. 258, G564-70.
Zima, T., et al., 1993. Plasma xanthine oxidase level and alcohol administration. Alcohol Alcohol. 28, 693-4.